AXSM (Axsome Therapeutics) GF Value Rank: 7 (As of Jul. 05, 2026) — 13% Below Median


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $244.31
GF Value $222.46
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics GF Value Rank?

Axsome Therapeutics AXSM +1.52% 52 GF Value Rank is 7 as of Jul. 05, 2026, which is 13% below its 10-year median of 8.00. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $222.46 (Fairly Valued). The stock has 4 warning signs investors should review.

Axsome Therapeutics has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Axsome Therapeutics GF Value Rank Related Terms

AXSM vs MDGL, IONS, BMRN: GF Value Rank Comparison

For the Biotechnology subindustry, Axsome Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's GF Value Rank falls into.


AXSM
52GF Score
Axsome Therapeutics Inc AXSM
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 7 mean?
Axsome Therapeutics (AXSM) has a GF Value Rank of 7 as of Jul. 05, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Axsome Therapeutics and its competitors. This is 13% below median its historical median of 8.00. Over the past decade, Axsome Therapeutics' GF Value Rank has ranged from 4.00 to 10.00.
Is Axsome Therapeutics' GF Value Rank too high?
Axsome Therapeutics' current GF Value Rank of 7 is 13% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' GF Value Rank compare to MDGL and IONS?
Axsome Therapeutics' GF Value Rank of 7 can be compared against companies in the Biotechnology industry. Historically, Axsome Therapeutics' own GF Value Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current GF Value Rank is 7, which is 13% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $222.46, compared to a current price of $244.31 — trading 9.8% above its estimated fair value. The current GF Value Rank is 7, which is 13% below median its 10-year median of 8.00. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current GF Value Rank is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $244.31 is trading 9.8% above its estimated GF Value™ of $222.46. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • GF Value Rank: 7 (13% below median its 10-year median of 8.00)
  • GF Value™: $222.46 vs. price of $244.31 (9.8% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$244.31
Price
$222.46
GF Value